Vogt-Koyanagi- Harada disease
Conditions
Interventions
1.The group given only prednisolone mPSL 1000mg Intravenous Infusion 3 days PSL 0.6~0.7 mg/kg Oral Administration 10 days PSL 0.5~0.6 mg/kg Oral Administration 10 days PSL 0.4~0.5 mg/kg Oral Admi
, CYA 3mg/kg is administered from day 4
Sponsors
Hokkaido University Graduate School of Medicine
Kyushu University Graduate School of Medicine National Defense Medical College Hospital Kagoshima University Graduate School of Medicine Kyorin University Hospital Yamaguchi University Hospital Kanazawa University Hospital Graduate School of Medicine, The University of Tokyo Kochi Medical School Hospital Kobe University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients of initial onset VKH disease who present all of a) to d) a) Within 4 weeks from disease onset b) Showing anterior chamber cells maximum 2+ c) Showing typical serous retinal detachment d) Without sunset glow fundus 2.Complete or incomplete type of VKH disease 3.Showing cerebrospinal fluid pleocytosis or meningeal irritation signs except headache alone 4.Who can recieve the treatment within 4 weeks from the disease onset
Exclusion criteria
Exclusion criteria: 1.Renal dysfunction 2.Immunosuppressant treatment including steroid 3.Immunocompromised condition 4.Females who are pregnant or lactating patients or who are suspicious of pregnant 5.Malignant neoplasm 6.Intraocular surgery (except for cataract surgery) or glaucoma surgery previously, or speculate to be required in the periods of this study 7.Investigator declare a subject ineligible for any sound reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of subjects showing recurrences of uveitis with VKH disease | — |
Countries
Japan
Contacts
Public ContactKazuomi Mizuuchi
Hokkaido University Graduate School of Medicine Department of Ophthalmology
Outcome results
None listed